• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 BAT-90 医疗器械对乳腺导管原位癌切除术后放射消融的新方法进行建模。

Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device.

机构信息

Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.

Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, 40126, Bologna, Italy.

出版信息

Sci Rep. 2022 Jan 7;12(1):14. doi: 10.1038/s41598-021-03807-6.

DOI:10.1038/s41598-021-03807-6
PMID:34996956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8741759/
Abstract

The majority of local recurrences, after conservative surgery of breast cancer, occurs in the same anatomical area where the tumour was originally located. For the treatment of ductal carcinoma in situ (DCIS), a new medical device, named BAT-90, (BetaGlue Technologies SpA) has been proposed. BAT-90 is based on the administration of Y β-emitting microspheres, embedded in a bio-compatible matrix. In this work, the Geant4 simulation toolkit is used to simulate BAT-90 as a homogenous cylindrical Y layer placed in the middle of a bulk material. The activity needed to deliver a 20 Gy isodose at a given distance z from the BAT-90 layer is calculated for different device thicknesses, tumour bed sizes and for water and adipose bulk materials. A radiobiological analysis has been performed using both the Poisson and logistic Tumour Control Probability (TCP) models. A range of radiobiological parameters (α and β), target sizes, and densities of tumour cells were considered. Increasing α values, TCP increases too, while, for a fixed α value, TCP decreases as a function of clonogenic cell density. The models predict very solid results in case of limited tumour burden while the activity/dose ratio could be further optimized in case of larger tumour beds.

摘要

大多数乳腺癌保乳手术后的局部复发发生在肿瘤最初所在的同一解剖区域。为了治疗导管原位癌(DCIS),一种名为 BAT-90 的新医疗器械(BetaGlue Technologies SpA)已被提出。BAT-90 基于 Yβ发射微球的给药,嵌入在生物相容的基质中。在这项工作中,Geant4 模拟工具包用于模拟 BAT-90 作为同质圆柱形 Y 层,放置在大块材料的中间。对于不同的设备厚度、肿瘤床大小以及水和脂肪体材料,计算了在距 BAT-90 层给定距离 z 处输送 20Gy 等剂量所需的活性。使用泊松和逻辑肿瘤控制概率(TCP)模型进行了放射生物学分析。考虑了一系列放射生物学参数(α和β)、靶标大小和肿瘤细胞密度。随着α值的增加,TCP 也会增加,而对于固定的α值,随着克隆形成细胞密度的增加,TCP 会降低。在肿瘤负担有限的情况下,这些模型预测结果非常可靠,而在肿瘤床较大的情况下,可以进一步优化活性/剂量比。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/4d55f7941536/41598_2021_3807_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/b49b8d317407/41598_2021_3807_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/5c40574052d9/41598_2021_3807_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/2ec255a7c75e/41598_2021_3807_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/d0b86ea2ded0/41598_2021_3807_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/8a411f51ee5e/41598_2021_3807_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/897b5680b9ea/41598_2021_3807_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/5aac0c90e49b/41598_2021_3807_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/607cdb692f5c/41598_2021_3807_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/4d55f7941536/41598_2021_3807_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/b49b8d317407/41598_2021_3807_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/5c40574052d9/41598_2021_3807_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/2ec255a7c75e/41598_2021_3807_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/d0b86ea2ded0/41598_2021_3807_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/8a411f51ee5e/41598_2021_3807_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/897b5680b9ea/41598_2021_3807_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/5aac0c90e49b/41598_2021_3807_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/607cdb692f5c/41598_2021_3807_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/8741759/4d55f7941536/41598_2021_3807_Fig9_HTML.jpg

相似文献

1
Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device.基于 BAT-90 医疗器械对乳腺导管原位癌切除术后放射消融的新方法进行建模。
Sci Rep. 2022 Jan 7;12(1):14. doi: 10.1038/s41598-021-03807-6.
2
Do we need to irradiate all small invasive breast cancers and DCIS?我们需要对所有小的浸润性乳腺癌和导管原位癌进行放射治疗吗?
Am Soc Clin Oncol Educ Book. 2013:40-4. doi: 10.14694/EdBook_AM.2013.33.40.
3
Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?导管原位癌(DCIS)的放射治疗:是否需要对瘤床进行追加放疗?
Neoplasma. 2006;53(6):507-10.
4
Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition.基于多参数 MRI-GTV 定义的外照射放疗前列腺癌肿瘤控制概率建模。
Radiat Oncol. 2020 Oct 20;15(1):242. doi: 10.1186/s13014-020-01683-4.
5
Accelerated partial breast irradiation for pure ductal carcinoma in situ.单纯导管原位癌的加速部分乳房照射。
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):403-8. doi: 10.1016/j.ijrobp.2010.05.030. Epub 2010 Aug 26.
6
Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study).保乳术后导管原位癌患者的大分割与常规分割全乳照射比较:一项来自全国多中心队列的倾向评分匹配分析(COBCG - 02研究)
J Cancer Res Clin Oncol. 2021 Jul;147(7):2069-2077. doi: 10.1007/s00432-020-03483-5. Epub 2021 Jan 2.
7
Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.145 例导管原位癌(DCIS)患者加速乳腺放疗 5 年的结果。
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e159-64. doi: 10.1016/j.ijrobp.2011.11.025.
8
Permanent breast seed implant for partial breast radiotherapy after partial mastectomy for favorable breast cancer: Technique, results, and applications to various seroma presentations.永久性乳腺籽源植入用于早期乳腺癌保乳术后的部分乳腺放疗:技术、结果及在各种血清肿表现中的应用
Brachytherapy. 2019 Jul-Aug;18(4):510-520. doi: 10.1016/j.brachy.2019.04.003. Epub 2019 May 17.
9
Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers.导管原位癌的放射治疗与第二非乳腺癌风险。
Breast Cancer Res Treat. 2017 Nov;166(1):299-306. doi: 10.1007/s10549-017-4410-6. Epub 2017 Jul 25.
10
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.非低危型导管原位癌保乳治疗及辅助放疗后的生活质量(BIG 3-07/TROG 07.01):一项随机、对照、III 期临床试验的 2 年结果。
Lancet Oncol. 2020 May;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20.

引用本文的文献

1
Large-scale foundation models and generative AI for BigData neuroscience.用于大数据神经科学的大规模基础模型和生成式人工智能。
Neurosci Res. 2024 Jun 17. doi: 10.1016/j.neures.2024.06.003.

本文引用的文献

1
Fully integrated Monte Carlo simulation for evaluating radiation induced DNA damage and subsequent repair using Geant4-DNA.使用 Geant4-DNA 进行全面集成的蒙特卡罗模拟,以评估辐射诱导的 DNA 损伤和随后的修复。
Sci Rep. 2020 Nov 27;10(1):20788. doi: 10.1038/s41598-020-75982-x.
2
Report on G4-Med, a Geant4 benchmarking system for medical physics applications developed by the Geant4 Medical Simulation Benchmarking Group.G4-Med 报告,这是一个由 Geant4 医疗模拟基准测试组开发的用于医学物理应用的 Geant4 基准测试系统。
Med Phys. 2021 Jan;48(1):19-56. doi: 10.1002/mp.14226. Epub 2020 Dec 12.
3
Incidence of Ductal Carcinoma in the United States, 2000-2014.
美国 2000-2014 年导管癌发病情况。
Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1316-1323. doi: 10.1158/1055-9965.EPI-18-1262. Epub 2019 Jun 11.
4
Comparison of radiobiological parameters for Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro.体外Y放射性核素治疗(RNT)与外照射放疗(EBRT)的放射生物学参数比较。
EJNMMI Phys. 2018 Sep 3;5(1):18. doi: 10.1186/s40658-018-0217-8.
5
Radiobiological parameters for breast cancer: a Monte Carlo analysis of START trial published results.乳腺癌的放射生物学参数:对START试验已发表结果的蒙特卡罗分析
Br J Radiol. 2018 Nov;91(1091):20170979. doi: 10.1259/bjr.20170979. Epub 2018 Jul 27.
6
Radiation repair models for clinical application.用于临床应用的辐射修复模型。
Br J Radiol. 2019 Jan;92(1093):20180070. doi: 10.1259/bjr.20180070. Epub 2018 Feb 28.
7
Postoperative radiotherapy after DCIS: Useful for whom?保乳术后乳腺导管原位癌的放射治疗:对谁有用?
Breast. 2017 Aug;34 Suppl 1:S43-S46. doi: 10.1016/j.breast.2017.06.026. Epub 2017 Jun 26.
8
Biology of high single doses of IORT: RBE, 5 R's, and other biological aspects.高单次剂量术中放疗的生物学:相对生物效应、5R 特性及其他生物学方面
Radiat Oncol. 2017 Jan 19;12(1):24. doi: 10.1186/s13014-016-0750-3.
9
Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement.加速部分乳腺照射:美国放射肿瘤学会循证共识声明更新版执行摘要
Pract Radiat Oncol. 2017 Mar-Apr;7(2):73-79. doi: 10.1016/j.prro.2016.09.007. Epub 2016 Sep 17.
10
Multi-catheter interstitial brachytherapy for partial breast irradiation: an audit of implant quality based on dosimetric evaluation comparing intra-operative versus post-operative placement.多导管组织间近距离放射疗法用于部分乳腺照射:基于剂量学评估对术中与术后放置进行比较的植入质量审核。
J Contemp Brachytherapy. 2016 Apr;8(2):116-21. doi: 10.5114/jcb.2016.59195. Epub 2016 Apr 14.